Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Despite magrolimab’s latest flop, efforts to target CD47 continue.
The latest clinical study listings reveal KRAS-targeting projects, ADCs and others starting phase 1.
Some light is shed on Dreamm-7, but precisely why this trial was successful remains a mystery.
Pelabresib's partial win at ASH was enough to persuade Novartis to pull the acquisition trigger.
Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.
On a wing and a prayer AbbVie takes livmoniplimab into phase 3.